Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRX246 in experimental fear and anxiety
NCT02922166Phase 1Unknown
- Sponsor
- Azevan Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anxiety disorder, post-traumatic stress disorder (PTSD) and intermittent explosive disorder (IED) comparing SRX246 with Placebo (2 arms). Primary endpoint: Change in startle reflex up to 7 days. Status: unknown.
02
Drugs
SRX246
03
Conditions
anxiety disorderpost-traumatic stress disorder (PTSD)intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT02922166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922166.